$5m Offtake Agreement Expands OTC-Medicine Business
Filed with ASX · · 4 pages · English
Summary by 6ix AI
This agreement aims to expand Xenitra's commercial pipeline and includes specific payment terms for each purchase order. The deal follows a previous procurement agreement and signifies a strategic move into the Food for Special Medical Purposes market in China. The company reported strong initial sales from its recently acquired subsidiary, Fukang, indicating positive growth potential in this sector.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Xenitra
- Investor Presentation
- Quarterly Activities/Appendix 4C Cash Flow Report
- Investor Webinar
- $12M offtake agreement with leading OTC-pharmaceutical
- $1.1m in OPAL-Tokenised Product Sales in First 7 Weeks
Later from Xenitra
- Trading Halt
- Proposed issue of securities - XEN
- Xenitra Raises $1.5m to Accelerate High-Margin Sales Growth
- Appendix 4E and Annual Report
- Appendix 4G and Corporate Governance Statement
Follow Xenitra into a list and get an email when it puts out news.
Follow Xenitra